^
CANCER:

Malignant Pleural Mesothelioma





Show legend
Group by Gene:
nivolumab
0
PD1 inhibitor
pembrolizumab
PD1 inhibitor
1
DNA synthesis inhibitor
gemcitabine
cisplatin
2
PD1 inhibitor, CTLA4 inhibitor
nivolumab + ipilimumab
3
Tubulin polymerization promoter
carboplatin
4
VEGF-A inhibitor
bevacizumab
5
Tubulin polymerization promoter, Thymidylate synthase inhibitor
carboplatin + raltitrexed
6
Tubulin polymerization inhibitor
vinorelbine tartrate
7
VEGFR-2 inhibitor
ramucirumab
8
TEAD1 inhibitor
IK-930
9
PD1 inhibitor, PARP inhibitor
niraparib + dostarlimab-gxly
10
PRMT5 inhibitor
MRTX1719
11
Wilms tumor 1 inhibitor, PD1 inhibitor
nivolumab + galinpepimut-S
12
ALK inhibitor
crizotinib
alectinib
13
T-cell stimulant, Mesothelin inhibitor
TC-210
14
THF dehydrogenase inhibitor, Thymidylate synthase inhibitor
pemetrexed
15
THF dehydrogenase inhibitor, Tubulin polymerization promoter, Thymidylate synthase inhibitor
carboplatin + pemetrexed
16
THF dehydrogenase inhibitor, DNA synthesis inhibitor, Thymidylate synthase inhibitor
cisplatin + pemetrexed
17
Chemotherapy
GC
18
PD-L1 inhibitor
PD-L1 inhibitor
19
THF dehydrogenase inhibitor, Arginine depleter, DNA synthesis inhibitor, Thymidylate synthase inhibitor
cisplatin + pemetrexed + pegargiminase
No biomarker
NF2 deletion
BAP1 mutation
PD-L1 expression
BAP1 deletion
PD-L1 overexpression
PD-L1 underexpression
RRM1 expression
MSLN overexpression
ASS1 mutation
MTAP deletion + PIK3CA mutation
BRCA2 mutation
ERCC1 expression
CD74-ROS1 fusion
MTAP deletion + CDKN2A deletion + CDKN2B deletion + BAP1 deletion
WT1 expression
TMB-L
EML4-ALK I1171N + EML4-ALK L1196M